<DOC>
	<DOCNO>NCT02529761</DOCNO>
	<brief_summary>This multicenter prospective nonrandomized study evaluate efficacy TACE combine sorafenib compare TACE monotherapy term overall survival intermediate-stage HCC .</brief_summary>
	<brief_title>TACE With Without Sorafenib Intermediate Stage Hepatocellular Carcinoma</brief_title>
	<detailed_description>Sorafenib , multikinase inhibitor , successfully apply solid tumor renal cancer HCC . According Barcelona Clinic Liver Cancer ( BCLC ) stag classification , transarterial chemoembolization ( TACE ) recommend first line-therapy patient intermediate stage - BCLC B class ( multinodular asymptomatic tumor without invasive pattern ) . Because sorafenib may improve efficacy locoregional therapy decrease post-TACE angiogenesis , sorafenib combination TACE attract considerable attention promising therapy</detailed_description>
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<mesh_term>Chlorotrianisene</mesh_term>
	<mesh_term>Niacinamide</mesh_term>
	<criteria>1 . Prior inform consent 2 . Intermediate stage HCC/ BCLC B stage 3 . Confirmed Diagnosis HCC : 1 . Cirrhotic subject : Clinical diagnosis AASLD criterion . HCC define cirrhotic subject one imaging technique ( CT scan , MRI , second generation contrast ultrasound ) show nodule large 2 cm contrast uptake arterial phase washout venous late phase two image technique show radiological behavior nodule 12 cm diameter . Cytohistological confirmation require subject fulfill eligibility criterion . 2 . Noncirrhotic subject : For subject without cirrhosis , histological cytological confirmation mandatory . Documentation original biopsy diagnosis acceptable 4 . Child Pugh class A/B ( 7 ) class without ascites hepatic encephalopathy 5 . ECOG Performance Status 01 6 . At least one unidimensional lesion measurable CTscan MRI accord RECIST 1.1 , mRECIST EASL criterion , respectively . 1 . Single lesion &gt; 5cm 2 . 23 lesion , least one lesion &gt; 3cm ; 4 lesion , limitation tumor size , sum size tumor lesion less 50 % liver parenchyma . 7 . Male female subject ≥ 18 year age 8 . Ability swallow oral medication 9 . Life expectancy least 12 week 10 . Pregnancy test negative within 14 day treatment . Both men woman enrol trial must use adequate barrier birth control measure course trial 4 week completion trial 11 . Adequate bone marrow , liver renal function assess central lab mean follow laboratory requirement sample within 7 day prior randomization : 1 . Hemoglobin &gt; 9.0 g/dl 2 . Absolute neutrophil count ( ANC ) &gt; 1,500/mm3 3 . Platelet count ≥50x109/L 4 . ALB ≥28g/L 5 . Total bilirubin &lt; 2 mg/dL 6 . ALT AST &lt; 5 x upper limit normal 7 . BUN creatinine &lt; 1.5 x upper limit normal 8 . INR &lt; 1.7 , PT &lt; 4 second control 1 . Diffuse HCC tumor size ≥50 % liver parenchyma 2 . Vascular invasion 3 . Presence extrahepatic metastasis 4 . Poor blood supply liver tumor lesion ; poor blood supply refers tumor lesion fail show obvious contrast uptake arterial phase washout venous late phase CT scan MRI 5 . Any contraindication hepatic embolization procedure : 1 . Known hepatofugal blood flow 2 . Known portosystemic shunt 3 . Renal failure / insufficiency require hemoor peritoneal dialysis 6 . Target lesion previously treat local therapy resection HCC , radiofrequency ablation ( RFA ) , percutaneous ethanol injection ( PEI ) 7 . Investigational drug molecular target drug ongoing complete &lt; 4 week prior baseline scan 8 . Prior transarterial embolization antitumor systemic chemotherapy 9 . Any ≥ CTC AE grade 2 acute toxic effect prior local treatment 10 . Patients untreated varix active bleed 11 . History cardiac disease : 1 . Congestive heart failure &gt; New York Heart Association ( NYHA ) class 2 2 . Uncontrolled hypertension 12 . Known history HIV infection 13 . Active clinically serious infection ( &gt; grade 2 NCICTCAE Version 4.0 ) , except HBV HCV infection 14 . Clinically significant gastrointestinal bleeding within 4 week prior start study drug 15 . Thrombotic embolic event cerebrovascular accident ( include transient ischemic attack ) , deep vein thrombosis pulmonary embolism within 6 month prior first dose study drug 16 . Previous concurrent cancer distinct primary site histology HCC . Any cancer curatively treat &gt; 3 year prior entry permit 17 . Any contraindication sorafenib doxorubicin administration 18 . Pregnant breastfeeding subject 19 . Any disease could affect evaluation study drug : unstable angina , active CAD , uncontrolled arrhythmia , myocardial infarction 20 . Any condition unstable could jeopardize safety subject compliance study 21 . Major surgery within 4 week prior start study drug ( e.g . thoracolaparotomy allow , noninvasive surgery , e.g . biopsy , allow ) 22 . Autologous bone marrow transplant stem cell rescue within 1 year prior start study drug 23 . History organ allograft</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
	<keyword>HCC</keyword>
	<keyword>sorafenib</keyword>
	<keyword>TACE</keyword>
	<keyword>overall survival</keyword>
</DOC>